GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
- Conditions
- Hepatitis CHIV
- Interventions
- Drug: SOFDrug: ATVDrug: EFVDrug: EFV/FTC/TDFDrug: RALDrug: ZDV/3TCDrug: FTC/TDFDrug: DRV
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 52
- Registration Number
- NCT01565889
- Locations
- 🇵🇷
Fundacion de Investigacion de Diego, San Juan, Puerto Rico
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
- Conditions
- Acquired Immunodeficiency SyndromeHIV Infections
- Interventions
- Drug: D/C/F/TAFDrug: DRVDrug: DRV PlaceboDrug: COBI PlaceboDrug: FTC/TDFDrug: FTC/TDF PlaceboDrug: D/C/F/TAF Placebo
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 153
- Registration Number
- NCT01565850
- Locations
- 🇺🇸
Peter J. Ruane, MD, Inc., Los Angeles, California, United States
🇺🇸North Shore University Hospital / Division of Infectious Diseases, Manhasset, New York, United States
🇺🇸Southwest Infectious Disease Clinical Research Inc, Dallas, Texas, United States
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
- Conditions
- Hepatitis CHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 61
- Registration Number
- NCT01559844
- Locations
- 🇺🇸
UCLA Medical Center-The Pfleger Liver Institute, Los Angeles, California, United States
🇺🇸St. Louis University Hospital, St. Louis, Missouri, United States
🇺🇸Baylor Health Care System, Dallas, Texas, United States
A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Behavioral: DietBehavioral: Exercise
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2014-09-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 442
- Registration Number
- NCT01555164
- Locations
- 🇺🇸
New Phase Research & Development, Knoxville, Tennessee, United States
🇺🇸National Research Institute, Los Angeles, California, United States
🇺🇸Baptist Diabetes Associates, Miami, Florida, United States
Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT01546558
- Locations
- 🇺🇸
SeaView Research Inc., Miami, Florida, United States
Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT01546597
- Locations
- 🇺🇸
Cetero Research, San Antonio, Texas, United States
Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 278
- Registration Number
- NCT01542788
- Locations
- 🇺🇸
Anthony Mills MD, Inc., Los Angeles, California, United States
🇺🇸Gastroenterology Associates, LLC, Baton Rouge, Louisiana, United States
🇺🇸Henry Ford Health System, Novi, Michigan, United States
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 220
- Registration Number
- NCT01539512
- Locations
- 🇺🇸
Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
🇺🇸Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸UCLA, Santa Monica, California, United States
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 161
- Registration Number
- NCT01539291
- Locations
- 🇺🇸
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇬🇧Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧Dorset County Hospital, Dorchester, United Kingdom
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
- Conditions
- Acquired Immunodeficiency SyndromeHIV Infections
- Interventions
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 48
- Registration Number
- NCT01533259
- Locations
- 🇺🇸
Kaiser Permanente Los Angeles, Los Angeles, California, United States
🇺🇸Anthony Mills MD, Inc, Los Angeles, California, United States
🇺🇸Peter J. Ruane, MD, Inc., Los Angeles, California, United States